Karoline Soares Garcia

Karoline Soares Garcia


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
KGKaroline Soares Garcia
Karoline Soares Garcia
MAMatheus Freitas Cardoso de Azevedo
Matheus Freitas Cardoso de Azevedo
ACAlexandre de Sousa Carlos
Alexandre de Sousa Carlos
LBLuisa Leite Barros
Luisa Leite Barros
JOJane Oba
Jane Oba
ADAderson Omar Mourão Cintra Damião
Aderson Omar Mourão Cintra Damião
Therapeutic drug monitoring (TDM) during induction therapy with anti-tumor necrosis factor drugs has emerged as a strategy to optimize response to these biologics and avoid undesired outcomes related to inadequate drug exposure. This study aimed to describe clinical, biological, and endoscopic remission rates at six months in Brazilian inflammatory bowel disease (IBD) patients following a proactive TDM algorithm guided by IFX trough levels (ITL) and antibodies to IFX (ATI) levels during induction, at week six. A total of 111 IBD patients were prospectively enrolled, excluding those previously exposed to the drug. ITL ≥ 10 μg/mL was considered optimal. Patients with suboptimal ITL ( 200 ng/mL discontinued IFX. In our study, proactive TDM was associated with persistence in the IFX rate at six months of 82.9%. At that time, rates of clinical, biological, and endoscopic remission in patients under IFX treatment were 80.2%, 73.9%, and 48.1%, respectively. Applying a simplified TDM-guided algorithm during induction seems feasible and can help improve patients’ outcomes in clinical practice.

30 September 2022 in Revista Paulista de Reumatologia
Verified
Journal Article
Closed access
KGKaroline Soares Garcia
Karoline Soares Garcia
ÁDÁlvaro Henrique de Almeida Delgado
Álvaro Henrique de Almeida Delgado
RBRicardo Correa Barbuti
Ricardo Correa Barbuti
TRTomás Navarro Rodriguez
Tomás Navarro Rodriguez
O acometimento esofágico por doenças autoimunes tem sido cada vez mais reportado na literatura. A incidência e a prevalência de esofagite eosinofílica têm aumentado nas últimas décadas e as opções terapêuticas têm evoluído bastante, mas o corticoide tópico e o uso de inibidores de bombas de prótons permanecem como excelentes opções terapêuticas. Diversas doenças sistêmicas autoimunes podem cursar com acometimento esofágico secundário, com prejuízos da motilidade do corpo esofágico e do esfíncter esofagiano inferior. Esse acometimento se traduz principalmente em disfagia e refluxo gastroesofágico patológico, com suas complicações associadas. Atenção deve ser dada ao tratamento da doença do refluxo gastroesofágico nesses pacientes, de tal forma a melhorar a qualidade de vida e evitar complicações, como esôfago de Barrett e estenoses pépticas. Unitermos: esclerose sistêmica; esofagite eosinofílica; manometria; disfagia; refluxo gastroesofágico.